You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLithium
Accession NumberDB01356
TypeSmall Molecule
GroupsApproved
DescriptionLithium was used during the 19th century to treat gout. Lithium salts such as lithium carbonate (Li2CO3), lithium citrate, and lithium orotate are mood stabilizers. They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression. Lithium can also be used to augment other antidepressant drugs. It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches. The active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several critical neuronal enzymes and neurotransmitter receptors.
Structure
Thumb
Synonyms
Li(+)
Lithium cation
Lithium ion
Lithium, ion
Lithium, ion (li1+)
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Carbolith Cap 150mgcapsule150 mgoralValeant Canada Lp Valeant Canada S.E.C.1979-12-31Not applicableCanada
Carbolith Cap 300mgcapsule300 mgoralValeant Canada Lp Valeant Canada S.E.C.1971-12-31Not applicableCanada
Carbolith Capsules 600mgcapsule600 mgoralValeant Canada Lp Valeant Canada S.E.C.1992-12-31Not applicableCanada
Dom-lithium Carbonatecapsule150 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-lithium Carbonatecapsule300 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-lithium Carbonatecapsule600 mgoralDominion PharmacalNot applicableNot applicableCanada
Duralith Tab 300mgtablet (extended-release)300 mgoralJanssen Inc1985-12-312010-02-12Canada
Euro Lithiumcapsule150 mgoralEuro Pharm International Canada Inc2008-02-262013-07-10Canada
Euro Lithiumcapsule300 mgoralEuro Pharm International Canada Inc2008-02-262013-07-10Canada
Lithanecapsule150 mgoralErfa Canada 2012 Inc1993-12-31Not applicableCanada
Lithanecapsule300 mgoralErfa Canada 2012 Inc1979-12-31Not applicableCanada
Lithiumsolution300 mg/5mLoralPrecision Dose Inc.2012-10-25Not applicableUs
Lithiumsolution8 meq/5mLoralRoxane Laboratories, Inc1982-04-29Not applicableUs
Lithiumsolution8 meq/5mLoralCardinal Health1982-04-29Not applicableUs
Lithiumsolution8 meq/5mLoralRoxane Laboratories, Inc1982-04-29Not applicableUs
Lithium Carbonatetablet300 mg/1oralRoxane Laboratories, Inc1982-06-14Not applicableUs
Lithium Carbonatecapsule, gelatin coated300 mg/1oralCardinal Health1987-07-28Not applicableUs
Lithium Carbonatecapsule, gelatin coated150 mg/1oralRoxane Laboratories, Inc1987-01-28Not applicableUs
Lithium Carbonatecapsule, gelatin coated150 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1987-01-28Not applicableUs
Lithium Carbonatecapsule, gelatin coated300 mg/1oralContract Pharmacy Services Pa2010-04-06Not applicableUs
Lithium Carbonatetablet300 mg/1oralRoxane Laboratories, Inc1982-01-29Not applicableUs
Lithium Carbonatecapsule, gelatin coated300 mg/1oralRoxane Laboratories, Inc1980-11-26Not applicableUs
Lithium Carbonatetablet300 mg/1oralSTAT Rx USA LLC1982-01-29Not applicableUs
Lithium Carbonatecapsule, gelatin coated150 mg/1oralRoxane Laboratories, Inc1987-01-28Not applicableUs
Lithium Carbonatecapsule, gelatin coated300 mg/1oralAphena Pharma Solutions Tennessee, Inc.1980-11-26Not applicableUs
Lithium Carbonatecapsule, gelatin coated600 mg/1oralRoxane Laboratories, Inc1987-01-28Not applicableUs
Lithium Carbonatecapsule, gelatin coated600 mg/1oralRoxane Laboratories, Inc1987-01-28Not applicableUs
Lithium Carbonatecapsule, gelatin coated300 mg/1oralREMEDYREPACK INC.2013-03-18Not applicableUs
Lithium Carbonatecapsule, gelatin coated300 mg/1oralRoxane Laboratories, Inc1987-07-28Not applicableUs
Lithium Carbonatecapsule, gelatin coated150 mg/1oralAphena Pharma Solutions Tennessee, Inc.1987-01-28Not applicableUs
Lithium Carbonatecapsule, gelatin coated300 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1980-11-26Not applicableUs
Lithium Carbonatecapsule, gelatin coated300 mg/1oralTYA Pharmaceuticals1980-11-26Not applicableUs
Lithium Carbonatecapsule, gelatin coated300 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Lithizine Cap 150mgcapsule150 mgoralLabs Maney Paul Labs, Division Of 471449 (Ont) Ltee/Ltd.1975-12-311997-08-19Canada
Lithizine Cap 300mgcapsule300 mgoralLabs Maney Paul Labs, Division Of 471449 (Ont) Ltee/Ltd.1975-12-311997-08-19Canada
Lithmaxtablet (extended-release)300 mgoralAa Pharma Inc2005-04-06Not applicableCanada
Lithobidtablet, film coated, extended release300 mg/1oralNOVEN THERAPEUTICS, LLC1979-04-27Not applicableUs
Lithobidtablet, film coated, extended release300 mg/1oralANI Pharmaceuticals, Inc.2014-07-01Not applicableUs
Pal-lithium Carbonatecapsule300 mgoralPaladin Labs Inc1998-03-032007-08-03Canada
Pal-lithium Carbonatecapsule600 mgoralPaladin Labs Inc1998-03-032007-08-03Canada
Pal-lithium Carbonatecapsule150 mgoralPaladin Labs Inc1998-03-032007-08-03Canada
PHL-lithium Carbonatecapsule300 mgoralPharmel Inc1998-02-172014-09-08Canada
PHL-lithium Carbonatecapsule600 mgoralPharmel Inc1998-02-172014-09-08Canada
PHL-lithium Carbonatecapsule150 mgoralPharmel Inc1998-02-172014-09-08Canada
PMS-lithium Carbonate - Cap 150mgcapsule150 mgoralPharmascience Inc1996-12-31Not applicableCanada
PMS-lithium Carbonate - Cap 300mgcapsule300 mgoralPharmascience Inc1996-12-31Not applicableCanada
PMS-lithium Carbonate - Cap 600mgcapsule600 mgoralPharmascience Inc1996-12-31Not applicableCanada
PMS-lithium Citratesyrup8 mmoloralPharmascience Inc1994-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-lithium Carbonatecapsule150 mgoralApotex Inc2001-02-12Not applicableCanada
Apo-lithium Carbonatecapsule300 mgoralApotex Inc2001-02-12Not applicableCanada
Lithium Carbonatetablet, film coated, extended release300 mg/1oralMylan Institutional Inc.2012-08-10Not applicableUs
Lithium Carbonatecapsule300 mg/1oralClinical Solutions Wholesale2009-12-15Not applicableUs
Lithium Carbonatetablet, film coated, extended release300 mg/1oralAmerican Health Packaging2012-03-052015-12-29Us
Lithium Carbonatetablet, film coated, extended release300 mg/1oralMylan Pharmaceuticals Inc.2012-07-25Not applicableUs
Lithium Carbonatecapsule600 mg/1oralHetero Drugs Limited2009-09-25Not applicableUs
Lithium Carbonatecapsule300 mg/1oralCamber Pharmaceuticals Inc.2009-12-15Not applicableUs
Lithium Carbonatecapsule300 mg/1oralPhysicians Total Care, Inc.1995-01-16Not applicableUs
Lithium Carbonatecapsule150 mg/1oralGlenmark Pharmaceuticals Inc., Usa2009-02-03Not applicableUs
Lithium Carbonatetablet, extended release450 mg/1oralRoxane Laboratories, Inc2004-01-05Not applicableUs
Lithium Carbonatecapsule300 mg/1oralbryant ranch prepack2003-03-01Not applicableUs
Lithium Carbonatecapsule300 mg/1oralREMEDYREPACK INC.2016-03-11Not applicableUs
Lithium Carbonatetablet, extended release450 mg/1oralMajor Pharmaceuticals2003-06-17Not applicableUs
Lithium Carbonatecapsule150 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Lithium Carbonatecapsule150 mg/1oralREMEDYREPACK INC.2013-05-08Not applicableUs
Lithium Carbonatecapsule300 mg/1oralGolden State Medical Supply, Inc.2015-08-04Not applicableUs
Lithium Carbonatecapsule150 mg/1oralWest Ward Pharmaceuticals Corp2003-03-01Not applicableUs
Lithium Carbonatetablet, film coated, extended release300 mg/1oralRising Pharmaceuticals, Inc.2016-01-01Not applicableUs
Lithium Carbonatetablet, extended release300 mg/1oralREMEDYREPACK INC.2011-04-13Not applicableUs
Lithium Carbonatetablet300 mg/1oralCardinal Health1982-01-29Not applicableUs
Lithium Carbonatecapsule300 mg/1oralContract Pharmacy Services Pa2010-04-06Not applicableUs
Lithium Carbonatecapsule300 mg/1oralREMEDYREPACK INC.2013-03-27Not applicableUs
Lithium Carbonatetablet, extended release450 mg/1oralMylan Pharmaceuticals Inc.2012-08-09Not applicableUs
Lithium Carbonatecapsule300 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2007-07-19Not applicableUs
Lithium Carbonatecapsule600 mg/1oralCamber Pharmaceuticals Inc.2009-12-15Not applicableUs
Lithium Carbonatecapsule150 mg/1oralPhysicians Total Care, Inc.2005-12-05Not applicableUs
Lithium Carbonatecapsule300 mg/1oralGlenmark Pharmaceuticals Inc., Usa2009-02-03Not applicableUs
Lithium Carbonatetablet, extended release300 mg/1oralRoxane Laboratories, Inc2004-10-28Not applicableUs
Lithium Carbonatecapsule150 mg/1oralMajor Pharmaceuticals2003-02-24Not applicableUs
Lithium Carbonatecapsule600 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Lithium Carbonatecapsule300 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Lithium Carbonatetablet, extended release300 mg/1oralCardinal Health2004-10-28Not applicableUs
Lithium Carbonatetablet, extended release450 mg/1oralAvera Mc Kennan Hospital2015-05-27Not applicableUs
Lithium Carbonatecapsule300 mg/1oralWest Ward Pharmaceuticals Corp2003-03-01Not applicableUs
Lithium Carbonatecapsule150 mg/1oralHetero Drugs Limited2009-09-25Not applicableUs
Lithium Carbonatetablet, extended release450 mg/1oralREMEDYREPACK INC.2011-05-17Not applicableUs
Lithium Carbonatetablet, film coated, extended release300 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2004-10-28Not applicableUs
Lithium Carbonatetablet, extended release300 mg/1oralAmerican Health Packaging2014-10-13Not applicableUs
Lithium Carbonatecapsule300 mg/1oralREMEDYREPACK INC.2013-02-09Not applicableUs
Lithium Carbonatecapsule300 mg/1oralHikma Pharmaceutical2002-06-27Not applicableUs
Lithium Carbonatetablet, extended release450 mg/1oralWest ward Pharmaceutical Corp2002-09-06Not applicableUs
Lithium Carbonatecapsule150 mg/1oralTYA Pharmaceuticals2009-12-15Not applicableUs
Lithium Carbonatecapsule300 mg/1oralAidarex Pharmaceuticals LLC2009-12-15Not applicableUs
Lithium Carbonatetablet, extended release300 mg/1oralPhysicians Total Care, Inc.2005-03-01Not applicableUs
Lithium Carbonatecapsule600 mg/1oralGlenmark Pharmaceuticals Inc., Usa2009-02-03Not applicableUs
Lithium Carbonatecapsule150 mg/1oralREMEDYREPACK INC.2015-10-20Not applicableUs
Lithium Carbonatecapsule150 mg/1oralREMEDYREPACK INC.2013-03-182016-03-12Us
Lithium Carbonatetablet, extended release450 mg/1oralCarilion Materials Management2004-01-05Not applicableUs
Lithium Carbonatecapsule300 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Lithium Carbonatetablet, extended release450 mg/1oralCardinal Health2003-06-17Not applicableUs
Lithium Carbonatetablet, extended release300 mg/1oralAvera Mc Kennan Hospital2015-04-16Not applicableUs
Lithium Carbonatecapsule600 mg/1oralWest Ward Pharmaceuticals Corp2002-05-01Not applicableUs
Lithium Carbonatecapsule300 mg/1oralHetero Drugs Limited2009-09-25Not applicableUs
Lithium Carbonatetablet, extended release450 mg/1oralMylan Institutional Inc.2012-04-20Not applicableUs
Lithium Carbonatetablet, film coated, extended release300 mg/1oralREMEDYREPACK INC.2016-01-19Not applicableUs
Lithium Carbonatecapsule300 mg/1oralMajor Pharmaceuticals2003-02-24Not applicableUs
Lithium Carbonatetablet, extended release450 mg/1oralAmerican Health Packaging2014-01-13Not applicableUs
Lithium Carbonatetablet300 mg/1oralREMEDYREPACK INC.2013-05-07Not applicableUs
Lithium Carbonatecapsule150 mg/1oralGolden State Medical Supply, Inc.2015-08-04Not applicableUs
Lithium Carbonatetablet, film coated, extended release300 mg/1oralGlenmark Pharmaceuticals Inc., Usa2010-12-27Not applicableUs
Lithium Carbonatetablet300 mg/1oralWest ward Pharmaceutical Corp2010-12-28Not applicableUs
Lithium Carbonatecapsule300 mg/1oralTYA Pharmaceuticals2009-12-15Not applicableUs
Lithium Carbonatecapsule300 mg/1oralPd Rx Pharmaceuticals, Inc.2003-03-01Not applicableUs
Lithium Carbonatetablet, extended release450 mg/1oralPhysicians Total Care, Inc.2005-06-22Not applicableUs
Lithium Carbonatetablet300 mg/1oralSun Pharmaceutical Industries Limited2010-07-08Not applicableUs
Lithium Carbonatecapsule150 mg/1oralCamber Pharmaceuticals Inc.2009-12-15Not applicableUs
Lithium Carbonatetablet, extended release300 mg/1oralCarilion Materials Management2004-10-28Not applicableUs
Lithium Carbonatecapsule300 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Lithium Carbonate ERtablet450 mg/1oralGlenmark Pharmaceuticals Inc., Usa2011-02-14Not applicableUs
Lithium Carbonate ERtablet450 mg/1oralClinical Solutions Wholesale, Llc2015-06-08Not applicableUs
Lithium Hydroxide Monohydratesolution8 meq/5mLoralMorton Grove Pharmaceuticals, Inc.1986-05-21Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EskalithNot Available
LithoTabNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Lithium carbonate
ThumbNot applicableDBSALT001075
Lithium citrate
ThumbNot applicableDBSALT001430
Lithium hydroxide monohydrate
ThumbNot applicableDBSALT001239
Categories
UNII9FN79X2M3F
CAS number7439-93-2
WeightAverage: 6.941
Monoisotopic: 7.016004049
Chemical FormulaLi
InChI KeyInChIKey=HBBGRARXTFLTSG-UHFFFAOYSA-N
InChI
InChI=1S/Li/q+1
IUPAC Name
lithium(1+) ion
SMILES
[Li+]
Taxonomy
DescriptionThis compound belongs to the class of inorganic compounds known as homogeneous alkali metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a alkali metal atom.
KingdomInorganic compounds
Super ClassHomogeneous metal compounds
ClassHomogeneous alkali metal compounds
Sub ClassNot Available
Direct ParentHomogeneous alkali metal compounds
Alternative ParentsNot Available
Substituents
  • Homogeneous alkali metal
  • Acyclic compound
Molecular FrameworkAcyclic compounds
External Descriptors
Pharmacology
IndicationLithium is used as a mood stabilizer, and is used for treatment of depression and mania. It is often used in bipolar disorder treatment.
PharmacodynamicsAlthough lithium has been used for over 50 years in treatment of bipolar disorder, the mechanism of action is still unknown. Lithium's therapeutic action may be due to a number of effects, ranging from inhibition of enzymes such as glycogen synthase kinase 3, inositol phosphatases, or modulation of glutamate receptors.
Mechanism of actionThe precise mechanism of action of Li+ as a mood-stabilizing agent is currently unknown. It is possible that Li+ produces its effects by interacting with the transport of monovalent or divalent cations in neurons. An increasing number of scientists have come to the conclusion that the excitatory neurotransmitter glutamate is the key factor in understanding how lithium works. Lithium has been shown to change the inward and outward currents of glutamate receptors (especially GluR3), without a shift in reversal potential. Lithium has been found to exert a dual effect on glutamate receptors, acting to keep the amount of glutamate active between cells at a stable, healthy level, neither too much nor too little. It is postulated that too much glutamate in the space between neurons causes mania, and too little, depression. Another mechanism by which lithium might help to regulate mood include the non-competitive inhibition of an enzyme called inositol monophosphatase. Alternately lithium's action may be enhanced through the deactivation of the GSK-3B enzyme. The regulation of GSK-3B by lithium may affect the circadian clock. GSK-3 is known for phosphorylating and thus inactivating glycogen synthase. GSK-3B has also been implicated in the control of cellular response to damaged DNA. GSK-3 normally phosphorylates beta catenin, which leads to beta catenin degratation. When GSK-3 is inhibited, beta catenin increases and transgenic mice with overexpression of beta catenin express similar behaviour to mice treated with lithium. These results suggest that increase of beta catenin may be a possible pathway for the therapeutic action of lithium.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8382
Blood Brain Barrier+0.9708
Caco-2 permeable+0.7056
P-glycoprotein substrateNon-substrate0.8831
P-glycoprotein inhibitor INon-inhibitor0.9869
P-glycoprotein inhibitor IINon-inhibitor0.9855
Renal organic cation transporterNon-inhibitor0.9199
CYP450 2C9 substrateNon-substrate0.8465
CYP450 2D6 substrateNon-substrate0.823
CYP450 3A4 substrateNon-substrate0.8094
CYP450 1A2 substrateNon-inhibitor0.8854
CYP450 2C9 inhibitorNon-inhibitor0.9224
CYP450 2D6 inhibitorNon-inhibitor0.9559
CYP450 2C19 inhibitorNon-inhibitor0.9487
CYP450 3A4 inhibitorNon-inhibitor0.9853
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9015
Ames testNon AMES toxic0.9663
CarcinogenicityCarcinogens 0.623
BiodegradationReady biodegradable0.9031
Rat acute toxicity2.0881 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9462
hERG inhibition (predictor II)Non-inhibitor0.9716
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsuleoral300 mg
Capsuleoral600 mg
Capsuleoral150 mg
Solutionoral300 mg/5mL
Solutionoral8 meq/5mL
Capsuleoral150 mg/1
Capsuleoral300 mg/1
Capsuleoral600 mg/1
Capsule, gelatin coatedoral150 mg/1
Capsule, gelatin coatedoral300 mg/1
Capsule, gelatin coatedoral600 mg/1
Tabletoral300 mg/1
Tablet, extended releaseoral300 mg/1
Tablet, extended releaseoral450 mg/1
Tablet, film coated, extended releaseoral300 mg/1
Tabletoral450 mg/1
Tablet (extended-release)oral300 mg
Syruporal8 mmol
Prices
Unit descriptionCostUnit
Eskalith cr 450 mg tablet0.8USD tablet
Lithium Carbonate 450 mg Controlled Release Tabs0.56USD tab
Lithium Carbonate 300 mg Controlled Release Tabs0.5USD tab
Lithium Carbonate 600 mg capsule0.44USD capsule
Lithium Carbonate 300 mg capsule0.29USD capsule
Lithium Carbonate 300 mg tablet0.29USD tablet
Lithate 20 mg capsule0.28USD capsule
Lithium carb powder reagent0.27USD g
Lithium carbonate 300 mg tab0.22USD each
Lithium Carbonate 150 mg capsule0.21USD capsule
Lithium Citrate 8meq/5ml Syrup0.15USD ml
Lithium citrate 8 meq/5 ml sol0.14USD ml
Pms-Lithium Carbonate 600 mg Capsule0.14USD capsule
Carbolith 150 mg Capsule0.13USD capsule
Lithate 5 mg capsule0.12USD capsule
Lithane 150 mg Capsule0.11USD capsule
Lithane 300 mg Capsule0.11USD capsule
Carbolith 300 mg Capsule0.1USD capsule
Apo-Lithium Carbonate 150 mg Capsule0.06USD capsule
Apo-Lithium Carbonate 300 mg Capsule0.06USD capsule
Pms-Lithium Carbonate 150 mg Capsule0.06USD capsule
Pms-Lithium Carbonate 300 mg Capsule0.06USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point0.512 g·cm −3Not Available
Predicted Properties
PropertyValueSource
logP0ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-0a4i-9000000000-d37172edddcf6ff27879View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-0a4i-9000000000-d37172edddcf6ff27879View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-0a4i-9000000000-d37172edddcf6ff27879View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-0a4i-9000000000-00619c7d65eb4b7f8f3dView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-0a4i-9000000000-00619c7d65eb4b7f8f3dView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-0a4i-9000000000-00619c7d65eb4b7f8f3dView in MoNA
References
Synthesis Reference

Jean-Paul Gabano, “Electrolyte for a lithium/thionyl chloride electric cell, a method of preparing said electrolyte and an electric cell which includes said electrolyte.” U.S. Patent US4375502, issued 0000.

US4375502
General References
  1. Quiroz JA, Machado-Vieira R, Zarate CA Jr, Manji HK: Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology. 2010;62(1):50-60. doi: 10.1159/000314310. Epub 2010 May 7. [PubMed:20453535 ]
External Links
ATC CodesN05AN01
AHFS Codes
  • 28:28.00
  • 92:02.00*
PDB EntriesNot Available
FDA labelDownload (200 KB)
MSDSDownload (72.1 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineLithium may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineLithium may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Lithium is combined with 7-Nitroindazole.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Lithium.
AceclofenacThe serum concentration of Lithium can be increased when it is combined with Aceclofenac.
AcepromazineLithium may increase the neurotoxic activities of Acepromazine.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Lithium.
AceprometazineLithium may increase the neurotoxic activities of Aceprometazine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Lithium.
AcetazolamideThe serum concentration of Lithium can be decreased when it is combined with Acetazolamide.
AcetophenazineLithium may increase the neurotoxic activities of Acetophenazine.
Acetylsalicylic acidThe serum concentration of Lithium can be increased when it is combined with Acetylsalicylic acid.
AdapaleneThe serum concentration of Lithium can be increased when it is combined with Adapalene.
adipiplonThe risk or severity of adverse effects can be increased when Lithium is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Lithium is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Lithium is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Lithium.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Lithium.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Lithium is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Lithium.
AmineptineLithium may increase the neurotoxic activities of Amineptine.
AminophyllineThe serum concentration of Lithium can be decreased when it is combined with Aminophylline.
AmiodaroneLithium may increase the QTc-prolonging activities of Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Lithium is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Lithium.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Lithium.
AmoxapineThe risk or severity of adverse effects can be increased when Lithium is combined with Amoxapine.
AmperozideLithium may increase the neurotoxic activities of Amperozide.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Lithium.
AmphetamineLithium may decrease the stimulatory activities of Amphetamine.
AnagrelideLithium may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe serum concentration of Lithium can be increased when it is combined with Antipyrine.
ApremilastThe serum concentration of Lithium can be increased when it is combined with Apremilast.
AripiprazoleLithium may increase the neurotoxic activities of Aripiprazole.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Lithium.
Arsenic trioxideLithium may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherLithium may increase the QTc-prolonging activities of Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Lithium is combined with Articaine.
AsenapineLithium may increase the neurotoxic activities of Asenapine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Lithium.
AzaperoneLithium may increase the neurotoxic activities of Azaperone.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Lithium.
AzapropazoneThe serum concentration of Lithium can be increased when it is combined with Azapropazone.
AzelastineLithium may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Lithium.
Azilsartan medoxomilThe serum concentration of Lithium can be increased when it is combined with Azilsartan medoxomil.
AzithromycinLithium may increase the QTc-prolonging activities of Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Lithium is combined with Baclofen.
BalsalazideThe serum concentration of Lithium can be increased when it is combined with Balsalazide.
BarbitalThe risk or severity of adverse effects can be increased when Lithium is combined with Barbital.
BedaquilineLithium may increase the QTc-prolonging activities of Bedaquiline.
BenazeprilThe serum concentration of Lithium can be increased when it is combined with Benazepril.
BendroflumethiazideBendroflumethiazide may decrease the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Lithium.
BenoxaprofenThe serum concentration of Lithium can be increased when it is combined with Benoxaprofen.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Lithium.
BenzphetamineLithium may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Lithium is combined with Benzyl alcohol.
BifeprunoxLithium may increase the neurotoxic activities of Bifeprunox.
BrexpiprazoleLithium may increase the neurotoxic activities of Brexpiprazole.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Lithium.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lithium.
BrimonidineThe risk or severity of adverse effects can be increased when Lithium is combined with Brimonidine.
BrinzolamideThe serum concentration of Lithium can be decreased when it is combined with Brinzolamide.
BromazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Bromazepam.
BromfenacThe serum concentration of Lithium can be increased when it is combined with Bromfenac.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lithium.
BrompheniramineThe risk or severity of adverse effects can be increased when Lithium is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Lithium is combined with Brotizolam.
BumetanideThe serum concentration of Lithium can be decreased when it is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lithium.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Lithium.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Lithium.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Lithium.
ButacaineThe risk or severity of adverse effects can be increased when Lithium is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Lithium is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Lithium is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Lithium.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Lithium.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Lithium.
CaffeineThe serum concentration of Lithium can be decreased when it is combined with Caffeine.
CandesartanThe serum concentration of Lithium can be increased when it is combined with Candesartan.
CandoxatrilThe serum concentration of Lithium can be increased when it is combined with Candoxatril.
CaptoprilThe serum concentration of Lithium can be increased when it is combined with Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Lithium.
CarbinoxamineThe risk or severity of adverse effects can be increased when Lithium is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Lithium is combined with Carfentanil.
CariprazineLithium may increase the neurotoxic activities of Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Lithium is combined with Carisoprodol.
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Lithium.
CarprofenThe serum concentration of Lithium can be increased when it is combined with Carprofen.
CastanospermineThe serum concentration of Lithium can be increased when it is combined with Castanospermine.
CelecoxibThe serum concentration of Lithium can be increased when it is combined with Celecoxib.
CeritinibLithium may increase the QTc-prolonging activities of Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Lithium is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Lithium is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lithium.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Lithium.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Lithium.
ChloroquineThe serum concentration of Lithium can be increased when it is combined with Chloroquine.
ChloroquineLithium may increase the QTc-prolonging activities of Chloroquine.
ChlorothiazideChlorothiazide may decrease the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
ChlorphenamineThe risk or severity of adverse effects can be increased when Lithium is combined with Chlorphenamine.
ChlorphentermineLithium may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineLithium may increase the neurotoxic activities of Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lithium.
ChlorprothixeneLithium may increase the neurotoxic activities of Chlorprothixene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Lithium.
ChlorthalidoneChlorthalidone may decrease the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Lithium is combined with Chlorzoxazone.
CilazaprilThe serum concentration of Lithium can be increased when it is combined with Cilazapril.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Lithium.
CiprofloxacinLithium may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideLithium may increase the QTc-prolonging activities of Cisapride.
CitalopramThe risk or severity of adverse effects can be increased when Lithium is combined with Citalopram.
ClarithromycinLithium may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe risk or severity of adverse effects can be increased when Lithium is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Lithium is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Lithium is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Lithium is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Lithium is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Lithium is combined with Clonidine.
ClonixinThe serum concentration of Lithium can be increased when it is combined with Clonixin.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lithium.
ClozapineLithium may increase the neurotoxic activities of Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Lithium.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Lithium.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Lithium.
CrizotinibLithium may increase the QTc-prolonging activities of Crizotinib.
CyamemazineLithium may increase the neurotoxic activities of Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Lithium is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lithium.
CyproheptadineThe risk or severity of adverse effects can be increased when Lithium is combined with Cyproheptadine.
D-LimoneneThe serum concentration of Lithium can be increased when it is combined with D-Limonene.
DantroleneThe risk or severity of adverse effects can be increased when Lithium is combined with Dantrolene.
DapiprazoleLithium may increase the neurotoxic activities of Dapiprazole.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Lithium.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Lithium.
deramciclaneThe risk or severity of adverse effects can be increased when Lithium is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Lithium.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Lithium.
DesloratadineThe risk or severity of adverse effects can be increased when Lithium is combined with Desloratadine.
DesmopressinThe therapeutic efficacy of Desmopressin can be decreased when used in combination with Lithium.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Lithium.
DetomidineThe risk or severity of adverse effects can be increased when Lithium is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Lithium is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lithium.
DextroamphetamineLithium may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Lithium.
DextromoramideThe risk or severity of adverse effects can be increased when Lithium is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Lithium.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Lithium.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Lithium.
DiclofenacThe serum concentration of Lithium can be increased when it is combined with Diclofenac.
DiclofenamideThe serum concentration of Lithium can be decreased when it is combined with Diclofenamide.
DifenoxinThe risk or severity of adverse effects can be increased when Lithium is combined with Difenoxin.
DiflunisalThe serum concentration of Lithium can be increased when it is combined with Diflunisal.
DihydrocodeineThe risk or severity of adverse effects can be increased when Lithium is combined with Dihydrocodeine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Lithium.
DihydroetorphineThe risk or severity of adverse effects can be increased when Lithium is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Lithium is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Lithium is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lithium.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lithium.
DisopyramideLithium may increase the QTc-prolonging activities of Disopyramide.
DofetilideLithium may increase the QTc-prolonging activities of Dofetilide.
DolasetronLithium may increase the QTc-prolonging activities of Dolasetron.
DolasetronDolasetron may increase the serotonergic activities of Lithium.
DomperidoneLithium may increase the QTc-prolonging activities of Domperidone.
DoramectinThe risk or severity of adverse effects can be increased when Lithium is combined with Doramectin.
DorzolamideThe serum concentration of Lithium can be decreased when it is combined with Dorzolamide.
DosulepinLithium may increase the neurotoxic activities of Dosulepin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Lithium.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Lithium.
DoxylamineThe risk or severity of adverse effects can be increased when Lithium is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Lithium is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Lithium.
DronedaroneLithium may increase the QTc-prolonging activities of Dronedarone.
DroperidolLithium may increase the neurotoxic activities of Droperidol.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Lithium.
DrotebanolThe risk or severity of adverse effects can be increased when Lithium is combined with Drotebanol.
DroxicamThe serum concentration of Lithium can be increased when it is combined with Droxicam.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Lithium.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Lithium.
DyphyllineThe serum concentration of Lithium can be decreased when it is combined with Dyphylline.
EcgonineThe risk or severity of adverse effects can be increased when Lithium is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Lithium is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Lithium is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Lithium.
EliglustatLithium may increase the QTc-prolonging activities of Eliglustat.
EnalaprilThe serum concentration of Lithium can be increased when it is combined with Enalapril.
EnalaprilatThe serum concentration of Lithium can be increased when it is combined with Enalaprilat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Lithium.
EntacaponeThe risk or severity of adverse effects can be increased when Lithium is combined with Entacapone.
EpirizoleThe serum concentration of Lithium can be increased when it is combined with Epirizole.
EplerenoneThe serum concentration of Lithium can be increased when it is combined with Eplerenone.
EprosartanThe serum concentration of Lithium can be increased when it is combined with Eprosartan.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lithium.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Lithium.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Lithium.
ErythromycinLithium may increase the QTc-prolonging activities of Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Lithium is combined with Escitalopram.
EsmirtazapineLithium may increase the neurotoxic activities of Esmirtazapine.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Lithium.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Lithium.
Etacrynic acidThe serum concentration of Lithium can be decreased when it is combined with Etacrynic acid.
EtanerceptThe serum concentration of Lithium can be increased when it is combined with Etanercept.
EthanolLithium may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Lithium.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lithium.
EthosuximideThe risk or severity of adverse effects can be increased when Lithium is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Lithium is combined with Ethotoin.
EthoxzolamideThe serum concentration of Lithium can be decreased when it is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Lithium is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Lithium is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Lithium is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Lithium is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Lithium is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Lithium is combined with Etizolam.
EtodolacThe serum concentration of Lithium can be increased when it is combined with Etodolac.
EtofenamateThe serum concentration of Lithium can be increased when it is combined with Etofenamate.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Lithium.
EtoperidoneThe risk or severity of adverse effects can be increased when Lithium is combined with Etoperidone.
EtoricoxibThe serum concentration of Lithium can be increased when it is combined with Etoricoxib.
EtorphineThe risk or severity of adverse effects can be increased when Lithium is combined with Etorphine.
Evening primrose oilThe serum concentration of Lithium can be increased when it is combined with Evening primrose oil.
exisulindThe serum concentration of Lithium can be increased when it is combined with exisulind.
EzogabineThe risk or severity of adverse effects can be increased when Lithium is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Lithium is combined with Felbamate.
FenbufenThe serum concentration of Lithium can be increased when it is combined with Fenbufen.
FencamfamineLithium may increase the neurotoxic activities of Fencamfamine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Lithium.
FenfluramineThe risk or severity of adverse effects can be increased when Lithium is combined with Fenfluramine.
FenoprofenThe serum concentration of Lithium can be increased when it is combined with Fenoprofen.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lithium.
FexofenadineThe risk or severity of adverse effects can be increased when Lithium is combined with Fexofenadine.
FlecainideLithium may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Lithium is combined with Flibanserin.
FloctafenineThe serum concentration of Lithium can be increased when it is combined with Floctafenine.
FludiazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Lithium is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Flunitrazepam.
FlunixinThe serum concentration of Lithium can be increased when it is combined with Flunixin.
FluoxetineThe risk or severity of adverse effects can be increased when Lithium is combined with Fluoxetine.
FlupentixolLithium may increase the neurotoxic activities of Flupentixol.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Lithium.
FluphenazineLithium may increase the neurotoxic activities of Fluphenazine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Lithium.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Lithium.
FlurbiprofenThe serum concentration of Lithium can be increased when it is combined with Flurbiprofen.
FluspirileneLithium may increase the neurotoxic activities of Fluspirilene.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Lithium.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Lithium is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Lithium is combined with Fluvoxamine.
ForasartanThe serum concentration of Lithium can be increased when it is combined with Forasartan.
FosinoprilThe serum concentration of Lithium can be increased when it is combined with Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Lithium.
FospropofolThe risk or severity of adverse effects can be increased when Lithium is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Lithium.
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Lithium.
FurosemideThe serum concentration of Lithium can be decreased when it is combined with Furosemide.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lithium.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Lithium is combined with gabapentin enacarbil.
Gadobenic acidLithium may increase the QTc-prolonging activities of Gadobenic acid.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Lithium is combined with Gamma Hydroxybutyric Acid.
GemifloxacinLithium may increase the QTc-prolonging activities of Gemifloxacin.
GlutethimideThe risk or severity of adverse effects can be increased when Lithium is combined with Glutethimide.
GoserelinLithium may increase the QTc-prolonging activities of Goserelin.
GranisetronLithium may increase the QTc-prolonging activities of Granisetron.
GranisetronGranisetron may increase the serotonergic activities of Lithium.
GuanfacineThe risk or severity of adverse effects can be increased when Lithium is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Lithium.
HaloperidolLithium may increase the neurotoxic activities of Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Lithium.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Lithium.
HeroinThe risk or severity of adverse effects can be increased when Lithium is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Lithium.
HMPL-004The serum concentration of Lithium can be increased when it is combined with HMPL-004.
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Lithium.
HydrochlorothiazideHydrochlorothiazide may decrease the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Lithium.
HydroflumethiazideHydroflumethiazide may decrease the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Lithium.
Hydroxyamphetamine hydrobromideLithium may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lithium.
HydroxyzineThe risk or severity of adverse effects can be increased when Lithium is combined with Hydroxyzine.
IbuprofenThe serum concentration of Lithium can be increased when it is combined with Ibuprofen.
IbuproxamThe serum concentration of Lithium can be increased when it is combined with Ibuproxam.
IbutilideLithium may increase the QTc-prolonging activities of Ibutilide.
IcatibantThe serum concentration of Lithium can be increased when it is combined with Icatibant.
IloperidoneLithium may increase the neurotoxic activities of Iloperidone.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Lithium.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Lithium.
IndalpineThe risk or severity of adverse effects can be increased when Lithium is combined with Indalpine.
IndapamideIndapamide may decrease the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
IndomethacinThe serum concentration of Lithium can be increased when it is combined with Indomethacin.
IndoprofenThe serum concentration of Lithium can be increased when it is combined with Indoprofen.
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Lithium.
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Lithium.
IrbesartanThe serum concentration of Lithium can be increased when it is combined with Irbesartan.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Lithium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Lithium.
IsoxicamThe serum concentration of Lithium can be increased when it is combined with Isoxicam.
KebuzoneThe serum concentration of Lithium can be increased when it is combined with Kebuzone.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Lithium.
KetazolamThe risk or severity of adverse effects can be increased when Lithium is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Lithium is combined with Ketobemidone.
KetoprofenThe serum concentration of Lithium can be increased when it is combined with Ketoprofen.
KetorolacThe serum concentration of Lithium can be increased when it is combined with Ketorolac.
LamotrigineThe risk or severity of adverse effects can be increased when Lithium is combined with Lamotrigine.
LeflunomideThe serum concentration of Lithium can be increased when it is combined with Leflunomide.
LenvatinibLithium may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideLithium may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe risk or severity of adverse effects can be increased when Lithium is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Lithium.
LevocabastineThe risk or severity of adverse effects can be increased when Lithium is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Lithium is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Lithium is combined with Levodopa.
LevofloxacinLithium may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Lithium.
LevomilnacipranThe risk or severity of adverse effects can be increased when Lithium is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Lithium.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Lithium.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Lithium.
LisdexamfetamineLithium may decrease the stimulatory activities of Lisdexamfetamine.
LisinoprilThe serum concentration of Lithium can be increased when it is combined with Lisinopril.
LofentanilThe risk or severity of adverse effects can be increased when Lithium is combined with Lofentanil.
LopinavirLithium may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Lithium is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Lithium.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Lithium.
LornoxicamThe serum concentration of Lithium can be increased when it is combined with Lornoxicam.
LosartanThe serum concentration of Lithium can be increased when it is combined with Losartan.
LoxapineLithium may increase the neurotoxic activities of Loxapine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Lithium.
LoxoprofenThe serum concentration of Lithium can be increased when it is combined with Loxoprofen.
Lu AA21004The risk or severity of adverse effects can be increased when Lithium is combined with Lu AA21004.
LumefantrineLithium may increase the QTc-prolonging activities of Lumefantrine.
LumiracoxibThe serum concentration of Lithium can be increased when it is combined with Lumiracoxib.
LurasidoneLithium may increase the neurotoxic activities of Lurasidone.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Lithium.
Magnesium salicylateThe serum concentration of Lithium can be increased when it is combined with Magnesium salicylate.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lithium.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Lithium is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Lithium.
MasoprocolThe serum concentration of Lithium can be increased when it is combined with Masoprocol.
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Lithium.
MeclizineThe risk or severity of adverse effects can be increased when Lithium is combined with Meclizine.
Meclofenamic acidThe serum concentration of Lithium can be increased when it is combined with Meclofenamic acid.
MedetomidineThe risk or severity of adverse effects can be increased when Lithium is combined with Medetomidine.
Mefenamic acidThe serum concentration of Lithium can be increased when it is combined with Mefenamic acid.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Lithium.
MeloxicamThe serum concentration of Lithium can be increased when it is combined with Meloxicam.
MelperoneLithium may increase the neurotoxic activities of Melperone.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Lithium.
MephentermineLithium may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Lithium.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Lithium.
MequitazineLithium may increase the arrhythmogenic activities of Mequitazine.
MesalazineThe serum concentration of Lithium can be increased when it is combined with Mesalazine.
MesoridazineLithium may increase the neurotoxic activities of Mesoridazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Lithium.
MetamizoleThe serum concentration of Lithium can be increased when it is combined with Metamizole.
MetaxaloneThe risk or severity of adverse effects can be increased when Lithium is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Lithium.
MethadoneLithium may increase the QTc-prolonging activities of Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Lithium is combined with Methadyl Acetate.
MethamphetamineLithium may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Lithium is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Lithium is combined with Methaqualone.
MethazolamideThe serum concentration of Lithium can be decreased when it is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Lithium is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Lithium.
MethotrimeprazineLithium may increase the neurotoxic activities of Methotrimeprazine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Lithium.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Lithium.
MethsuximideThe risk or severity of adverse effects can be increased when Lithium is combined with Methsuximide.
MethyclothiazideMethyclothiazide may decrease the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Lithium.
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Lithium.
MethylphenidateThe risk or severity of adverse effects can be increased when Lithium is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Lithium.
MetoclopramideThe risk or severity of adverse effects can be increased when Lithium is combined with Metoclopramide.
MetolazoneMetolazone may decrease the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
MetyrosineLithium may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Lithium.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Lithium.
MifepristoneMifepristone may increase the QTc-prolonging activities of Lithium.
MilnacipranThe risk or severity of adverse effects can be increased when Lithium is combined with Milnacipran.
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Lithium.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lithium.
MirtazapineLithium may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Lithium.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Lithium.
MoexiprilThe serum concentration of Lithium can be increased when it is combined with Moexipril.
MolindoneLithium may increase the neurotoxic activities of Molindone.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Lithium.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Lithium.
MoxifloxacinLithium may increase the QTc-prolonging activities of Moxifloxacin.
Mycophenolate mofetilThe serum concentration of Lithium can be increased when it is combined with Mycophenolate mofetil.
Mycophenolic acidThe serum concentration of Lithium can be increased when it is combined with Mycophenolic acid.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Lithium.
NabiloneThe risk or severity of adverse effects can be increased when Lithium is combined with Nabilone.
NabumetoneThe serum concentration of Lithium can be increased when it is combined with Nabumetone.
NaftifineThe serum concentration of Lithium can be increased when it is combined with Naftifine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Lithium.
NaproxenThe serum concentration of Lithium can be increased when it is combined with Naproxen.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Lithium.
NCX 4016The serum concentration of Lithium can be increased when it is combined with NCX 4016.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Lithium.
NepafenacThe serum concentration of Lithium can be increased when it is combined with Nepafenac.
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Lithium.
Niflumic AcidThe serum concentration of Lithium can be increased when it is combined with Niflumic Acid.
NilotinibLithium may increase the QTc-prolonging activities of Nilotinib.
NimesulideThe serum concentration of Lithium can be increased when it is combined with Nimesulide.
NitrazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Lithium is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Lithium is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Lithium.
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Lithium.
OfloxacinLithium may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineLithium may increase the neurotoxic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Lithium.
OlmesartanThe serum concentration of Lithium can be increased when it is combined with Olmesartan.
OlopatadineThe risk or severity of adverse effects can be increased when Lithium is combined with Olopatadine.
OlsalazineThe serum concentration of Lithium can be increased when it is combined with Olsalazine.
OmapatrilatThe serum concentration of Lithium can be increased when it is combined with Omapatrilat.
OndansetronLithium may increase the neurotoxic activities of Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Lithium.
OpiumThe risk or severity of adverse effects can be increased when Lithium is combined with Opium.
OrgoteinThe serum concentration of Lithium can be increased when it is combined with Orgotein.
OrphenadrineLithium may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Lithium.
OsanetantLithium may increase the neurotoxic activities of Osanetant.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Lithium.
OxaprozinThe serum concentration of Lithium can be increased when it is combined with Oxaprozin.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Lithium.
OxprenololThe risk or severity of adverse effects can be increased when Lithium is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Lithium.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lithium.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Lithium.
OxyphenbutazoneThe serum concentration of Lithium can be increased when it is combined with Oxyphenbutazone.
PaliperidoneLithium may increase the neurotoxic activities of Paliperidone.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Lithium.
PalonosetronPalonosetron may increase the serotonergic activities of Lithium.
PanobinostatLithium may increase the QTc-prolonging activities of Panobinostat.
ParaldehydeLithium may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Lithium.
ParecoxibThe serum concentration of Lithium can be increased when it is combined with Parecoxib.
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Lithium.
ParoxetineThe risk or severity of adverse effects can be increased when Lithium is combined with Paroxetine.
PazopanibLithium may increase the QTc-prolonging activities of Pazopanib.
PentamidineLithium may increase the QTc-prolonging activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lithium.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Lithium.
PerampanelThe risk or severity of adverse effects can be increased when Lithium is combined with Perampanel.
PerflutrenLithium may increase the QTc-prolonging activities of Perflutren.
PerindoprilThe serum concentration of Lithium can be increased when it is combined with Perindopril.
PerospironeLithium may increase the neurotoxic activities of Perospirone.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Lithium.
PerphenazineLithium may increase the neurotoxic activities of Perphenazine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Lithium.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Lithium.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Lithium.
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Lithium.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Lithium.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Lithium is combined with Phenoxyethanol.
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Lithium.
PhentermineLithium may decrease the stimulatory activities of Phentermine.
PhenylbutazoneThe serum concentration of Lithium can be increased when it is combined with Phenylbutazone.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Lithium.
PimecrolimusThe serum concentration of Lithium can be increased when it is combined with Pimecrolimus.
PimozideLithium may increase the neurotoxic activities of Pimozide.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Lithium.
PipamperoneLithium may increase the neurotoxic activities of Pipamperone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Lithium.
PipotiazineLithium may increase the neurotoxic activities of Pipotiazine.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Lithium.
PiretanideThe serum concentration of Lithium can be decreased when it is combined with Piretanide.
PirfenidoneThe serum concentration of Lithium can be increased when it is combined with Pirfenidone.
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Lithium.
PiroxicamThe serum concentration of Lithium can be increased when it is combined with Piroxicam.
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Lithium.
PizotifenThe risk or severity of adverse effects can be increased when Lithium is combined with Pizotifen.
Polystyrene sulfonateThe serum concentration of Lithium can be decreased when it is combined with Polystyrene sulfonate.
PolythiazidePolythiazide may decrease the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
PomalidomideThe risk or severity of adverse effects can be increased when Lithium is combined with Pomalidomide.
Potassium IodidePotassium Iodide may increase the hypothyroid activities of Lithium.
PramipexoleLithium may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Lithium is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Lithium.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Lithium.
PrimaquineLithium may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Lithium is combined with Primidone.
ProcainamideLithium may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Lithium.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Lithium.
ProchlorperazineLithium may increase the neurotoxic activities of Prochlorperazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lithium.
PromazineLithium may increase the neurotoxic activities of Promazine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Lithium.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Lithium.
PropacetamolThe serum concentration of Lithium can be increased when it is combined with Propacetamol.
PropafenoneLithium may increase the QTc-prolonging activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Lithium.
PropericiazineLithium may increase the neurotoxic activities of Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Lithium.
PropoxycaineThe risk or severity of adverse effects can be increased when Lithium is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Lithium.
PSD502The risk or severity of adverse effects can be increased when Lithium is combined with PSD502.
PTC299The serum concentration of Lithium can be increased when it is combined with PTC299.
QuazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Quazepam.
QuetiapineLithium may increase the neurotoxic activities of Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lithium.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Lithium.
QuinaprilThe serum concentration of Lithium can be increased when it is combined with Quinapril.
QuinethazoneQuinethazone may decrease the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
QuinidineLithium may increase the QTc-prolonging activities of Quinidine.
QuinineLithium may increase the QTc-prolonging activities of Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Lithium is combined with Ramelteon.
RamiprilThe serum concentration of Lithium can be increased when it is combined with Ramipril.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Lithium.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lithium.
RemoxiprideLithium may increase the neurotoxic activities of Remoxipride.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Lithium.
RescinnamineThe serum concentration of Lithium can be increased when it is combined with Rescinnamine.
ReserpineLithium may increase the neurotoxic activities of Reserpine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Lithium.
ResveratrolThe serum concentration of Lithium can be increased when it is combined with Resveratrol.
RisperidoneLithium may increase the neurotoxic activities of Risperidone.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Lithium.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Lithium.
RofecoxibThe serum concentration of Lithium can be increased when it is combined with Rofecoxib.
RomifidineThe risk or severity of adverse effects can be increased when Lithium is combined with Romifidine.
RopiniroleLithium may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Lithium.
RotigotineLithium may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Lithium.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Lithium is combined with S-Ethylisothiourea.
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Lithium.
SalicylamideThe serum concentration of Lithium can be increased when it is combined with Salicylamide.
Salicylic acidThe serum concentration of Lithium can be increased when it is combined with Salicylic acid.
SalsalateThe serum concentration of Lithium can be increased when it is combined with Salsalate.
SaprisartanThe serum concentration of Lithium can be increased when it is combined with Saprisartan.
SaquinavirLithium may increase the QTc-prolonging activities of Saquinavir.
SaralasinThe serum concentration of Lithium can be increased when it is combined with Saralasin.
ScopolamineThe risk or severity of adverse effects can be increased when Lithium is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Lithium.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Lithium.
SeratrodastThe serum concentration of Lithium can be increased when it is combined with Seratrodast.
SertindoleLithium may increase the neurotoxic activities of Sertindole.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Lithium.
SertralineThe risk or severity of adverse effects can be increased when Lithium is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lithium.
Sodium bicarbonateSodium bicarbonate may increase the excretion rate of Lithium which could result in a higher serum level.
Sodium ChlorideSodium Chloride may increase the excretion rate of Lithium which could result in a higher serum level.
Sodium oxybateThe risk or severity of adverse effects can be increased when Lithium is combined with Sodium oxybate.
SotalolLithium may increase the QTc-prolonging activities of Sotalol.
SpiraprilThe serum concentration of Lithium can be increased when it is combined with Spirapril.
SRT501The serum concentration of Lithium can be increased when it is combined with SRT501.
StiripentolThe risk or severity of adverse effects can be increased when Lithium is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lithium.
SulfasalazineThe serum concentration of Lithium can be increased when it is combined with Sulfasalazine.
SulfisoxazoleLithium may increase the QTc-prolonging activities of Sulfisoxazole.
SulindacThe serum concentration of Lithium can be increased when it is combined with Sulindac.
SulpirideThe risk or severity of adverse effects can be increased when Lithium is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Lithium.
SuprofenThe serum concentration of Lithium can be increased when it is combined with Suprofen.
SuvorexantThe risk or severity of adverse effects can be increased when Lithium is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Lithium.
TasimelteonThe risk or severity of adverse effects can be increased when Lithium is combined with Tasimelteon.
TasosartanThe serum concentration of Lithium can be increased when it is combined with Tasosartan.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Lithium.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Lithium is combined with Tedizolid Phosphate.
TelavancinLithium may increase the QTc-prolonging activities of Telavancin.
TelithromycinLithium may increase the QTc-prolonging activities of Telithromycin.
TelmisartanThe serum concentration of Lithium can be increased when it is combined with Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Lithium.
TemocaprilThe serum concentration of Lithium can be increased when it is combined with Temocapril.
TenoxicamThe serum concentration of Lithium can be increased when it is combined with Tenoxicam.
TepoxalinThe serum concentration of Lithium can be increased when it is combined with Tepoxalin.
TeriflunomideThe serum concentration of Lithium can be increased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Lithium.
TetracaineThe risk or severity of adverse effects can be increased when Lithium is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Lithium is combined with Tetrodotoxin.
ThalidomideLithium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Lithium.
TheophyllineThe serum concentration of Lithium can be decreased when it is combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Lithium.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Lithium.
ThioproperazineLithium may increase the neurotoxic activities of Thioproperazine.
ThioridazineLithium may increase the neurotoxic activities of Thioridazine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Lithium.
ThiothixeneLithium may increase the neurotoxic activities of Thiothixene.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Lithium.
TiagabineThe risk or severity of adverse effects can be increased when Lithium is combined with Tiagabine.
TianeptineLithium may increase the neurotoxic activities of Tianeptine.
Tiaprofenic acidThe serum concentration of Lithium can be increased when it is combined with Tiaprofenic acid.
TiletamineThe risk or severity of adverse effects can be increased when Lithium is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Lithium is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Lithium is combined with Tolcapone.
Tolfenamic AcidThe serum concentration of Lithium can be increased when it is combined with Tolfenamic Acid.
TolmetinThe serum concentration of Lithium can be increased when it is combined with Tolmetin.
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Lithium.
TopiramateThe serum concentration of Lithium can be increased when it is combined with Topiramate.
TopiramateThe risk or severity of adverse effects can be increased when Lithium is combined with Topiramate.
TorasemideThe serum concentration of Lithium can be decreased when it is combined with Torasemide.
ToremifeneLithium may increase the QTc-prolonging activities of Toremifene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Lithium.
TrandolaprilThe serum concentration of Lithium can be increased when it is combined with Trandolapril.
TranilastThe serum concentration of Lithium can be increased when it is combined with Tranilast.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Lithium is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lithium.
TrazodoneThe risk or severity of adverse effects can be increased when Lithium is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Lithium.
TrichlormethiazideTrichlormethiazide may decrease the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
TrifluoperazineLithium may increase the neurotoxic activities of Trifluoperazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lithium.
TriflupromazineLithium may increase the neurotoxic activities of Triflupromazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Lithium.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Lithium.
TriprolidineThe risk or severity of adverse effects can be increased when Lithium is combined with Triprolidine.
Trisalicylate-cholineThe serum concentration of Lithium can be increased when it is combined with Trisalicylate-choline.
ValdecoxibThe serum concentration of Lithium can be increased when it is combined with Valdecoxib.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Lithium.
ValsartanThe serum concentration of Lithium can be increased when it is combined with Valsartan.
VandetanibLithium may increase the QTc-prolonging activities of Vandetanib.
VemurafenibLithium may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Lithium.
VigabatrinThe risk or severity of adverse effects can be increased when Lithium is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Lithium is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Lithium is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Lithium is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Lithium.
ZaltoprofenThe serum concentration of Lithium can be increased when it is combined with Zaltoprofen.
ZiconotideThe risk or severity of adverse effects can be increased when Lithium is combined with Ziconotide.
ZileutonThe serum concentration of Lithium can be increased when it is combined with Zileuton.
ZimelidineThe risk or severity of adverse effects can be increased when Lithium is combined with Zimelidine.
ZiprasidoneLithium may increase the neurotoxic activities of Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Lithium.
ZolazepamThe risk or severity of adverse effects can be increased when Lithium is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Lithium.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Lithium.
ZomepiracThe serum concentration of Lithium can be increased when it is combined with Zomepirac.
ZonisamideThe risk or severity of adverse effects can be increased when Lithium is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Lithium.
ZotepineLithium may increase the neurotoxic activities of Zotepine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Lithium.
ZuclopenthixolLithium may increase the neurotoxic activities of Zuclopenthixol.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lithium.
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid iodine supplements.
  • Do not change your salt intake from day to day without telling your doctor.
  • Take with food to reduce irritation. Drink plenty of liquids.

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Ubiquitin protein ligase binding
Specific Function:
Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires primed phosphorylation of the majo...
Gene Name:
GSK3B
Uniprot ID:
P49841
Molecular Weight:
46743.865 Da
References
  1. Borsotto M, Cavarec L, Bouillot M, Romey G, Macciardi F, Delaye A, Nasroune M, Bastucci M, Sambucy JL, Luan JJ, Charpagne A, Jouet V, Leger R, Lazdunski M, Cohen D, Chumakov I: PP2A-Bgamma subunit and KCNQ2 K+ channels in bipolar disorder. Pharmacogenomics J. 2007 Apr;7(2):123-32. Epub 2006 May 30. [PubMed:16733521 ]
  2. Adli M, Hollinde DL, Stamm T, Wiethoff K, Tsahuridu M, Kirchheiner J, Heinz A, Bauer M: Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism. Biol Psychiatry. 2007 Dec 1;62(11):1295-302. Epub 2007 Jul 12. [PubMed:17628506 ]
  3. O'Brien WT, Klein PS: Validating GSK3 as an in vivo target of lithium action. Biochem Soc Trans. 2009 Oct;37(Pt 5):1133-8. doi: 10.1042/BST0371133. [PubMed:19754466 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Protein homodimerization activity
Specific Function:
Responsible for the provision of inositol required for synthesis of phosphatidylinositol and polyphosphoinositides and has been implicated as the pharmacological target for lithium action in brain. Has broad substrate specificity and can use myo-inositol monophosphates, myo-inositol 1,3-diphosphate, myo-inositol 1,4-diphosphate, scyllo-inositol-phosphate, D-galactose 1-phosphate, glucose-1-phos...
Gene Name:
IMPA1
Uniprot ID:
P29218
Molecular Weight:
30188.59 Da
References
  1. Sarkar S, Rubinsztein DC: Inositol and IP3 levels regulate autophagy: biology and therapeutic speculations. Autophagy. 2006 Apr-Jun;2(2):132-4. Epub 2006 Apr 6. [PubMed:16874097 ]
  2. Trinquet E, Fink M, Bazin H, Grillet F, Maurin F, Bourrier E, Ansanay H, Leroy C, Michaud A, Durroux T, Maurel D, Malhaire F, Goudet C, Pin JP, Naval M, Hernout O, Chretien F, Chapleur Y, Mathis G: D-myo-inositol 1-phosphate as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor G protein-coupled receptor activation. Anal Biochem. 2006 Nov 1;358(1):126-35. Epub 2006 Aug 30. [PubMed:16965760 ]
  3. Ohnishi T, Ohba H, Seo KC, Im J, Sato Y, Iwayama Y, Furuichi T, Chung SK, Yoshikawa T: Spatial expression patterns and biochemical properties distinguish a second myo-inositol monophosphatase IMPA2 from IMPA1. J Biol Chem. 2007 Jan 5;282(1):637-46. Epub 2006 Oct 26. [PubMed:17068342 ]
  4. Tanizawa Y, Kuhara A, Inada H, Kodama E, Mizuno T, Mori I: Inositol monophosphatase regulates localization of synaptic components and behavior in the mature nervous system of C. elegans. Genes Dev. 2006 Dec 1;20(23):3296-310. [PubMed:17158747 ]
  5. Ohnishi T, Yamada K, Ohba H, Iwayama Y, Toyota T, Hattori E, Inada T, Kunugi H, Tatsumi M, Ozaki N, Iwata N, Sakamoto K, Iijima Y, Iwata Y, Tsuchiya KJ, Sugihara G, Nanko S, Osumi N, Detera-Wadleigh SD, Kato T, Yoshikawa T: A promoter haplotype of the inositol monophosphatase 2 gene (IMPA2) at 18p11.2 confers a possible risk for bipolar disorder by enhancing transcription. Neuropsychopharmacology. 2007 Aug;32(8):1727-37. Epub 2007 Jan 24. [PubMed:17251911 ]
  6. Li Z, Stieglitz KA, Shrout AL, Wei Y, Weis RM, Stec B, Roberts MF: Mobile loop mutations in an archaeal inositol monophosphatase: modulating three-metal ion assisted catalysis and lithium inhibition. Protein Sci. 2010 Feb;19(2):309-18. doi: 10.1002/pro.315. [PubMed:20027624 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Protein homodimerization activity
Specific Function:
Can use myo-inositol monophosphates, scylloinositol 1,4-diphosphate, glucose-1-phosphate, beta-glycerophosphate, and 2'-AMP as substrates. Has been implicated as the pharmacological target for lithium Li(+) action in brain.
Gene Name:
IMPA2
Uniprot ID:
O14732
Molecular Weight:
31320.525 Da
References
  1. Cryns K, Shamir A, Shapiro J, Daneels G, Goris I, Van Craenendonck H, Straetemans R, Belmaker RH, Agam G, Moechars D, Steckler T: Lack of lithium-like behavioral and molecular effects in IMPA2 knockout mice. Neuropsychopharmacology. 2007 Apr;32(4):881-91. Epub 2006 Jul 12. [PubMed:16841073 ]
  2. Ohnishi T, Ohba H, Seo KC, Im J, Sato Y, Iwayama Y, Furuichi T, Chung SK, Yoshikawa T: Spatial expression patterns and biochemical properties distinguish a second myo-inositol monophosphatase IMPA2 from IMPA1. J Biol Chem. 2007 Jan 5;282(1):637-46. Epub 2006 Oct 26. [PubMed:17068342 ]
  3. Ohnishi T, Yamada K, Ohba H, Iwayama Y, Toyota T, Hattori E, Inada T, Kunugi H, Tatsumi M, Ozaki N, Iwata N, Sakamoto K, Iijima Y, Iwata Y, Tsuchiya KJ, Sugihara G, Nanko S, Osumi N, Detera-Wadleigh SD, Kato T, Yoshikawa T: A promoter haplotype of the inositol monophosphatase 2 gene (IMPA2) at 18p11.2 confers a possible risk for bipolar disorder by enhancing transcription. Neuropsychopharmacology. 2007 Aug;32(8):1727-37. Epub 2007 Jan 24. [PubMed:17251911 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
potentiator
General Function:
Extracellular-glutamate-gated ion channel activity
Specific Function:
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and t...
Gene Name:
GRIA3
Uniprot ID:
P42263
Molecular Weight:
101155.975 Da
References
  1. Karkanias NB, Papke RL: Lithium modulates desensitization of the glutamate receptor subtype gluR3 in Xenopus oocytes. Neurosci Lett. 1999 Dec 31;277(3):153-6. [PubMed:10626836 ]
Comments
comments powered by Disqus
Drug created on July 06, 2007 13:50 / Updated on August 17, 2016 12:23